Cannabidiol for the Treatment of Pelvic Pain in Endometriosis (DREAMLAND) (DREAMLAND)
Cannabidiol in the Treatment of Women With Chronic Pelvic Pain Secondary to Endometriosis
Sponsor: University of Sao Paulo
Terminated
The study was prematurely terminated due to the results of the interim analysis conducted, as outlined in the initial project plan.
Other terminated trials from University of Sao Paulo
Listed as NCT05670353, this PHASE2/PHASE3 trial focuses on Endometriosis and Pelvic Pain and remains terminated or withdrawn. Sponsored by University of Sao Paulo, it has been updated 7 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
May 2025 — Present [monthly]
Terminated PHASE2/PHASE3
Status: Recruiting → Terminated
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2023 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 2 earlier versions
-
Jun 2023 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Enrolling By Invitation → Recruiting
-
Feb 2023 — Jun 2023 [monthly]
Enrolling By Invitation PHASE2_PHASE3
First recorded
Jan 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Sao Paulo
For direct contact, visit the study record on ClinicalTrials.gov .